Olema Pharmaceuticals, Inc. Liquidation Value
OLMA
Other
Cash & Equivalents
$48.30M
As of 2025-12-31
Current Price: N/A
Key Metrics
Cash Liquidation Value
Cash minus Total Obligations
Cash: $48.30M
Total Obligations: -$52.99M
$-4.69M
Per share: $-0.06
Period: 2025-12-31
Liquid Liquidation Value
Cash + AR minus Total Obligations
Cash: $48.30M
AR: $0
Total Obligations: -$52.99M
$-4.69M
Per share: $-0.06
Period: 2025-12-31
Operating Liquidation Value
Cash + AR + Inventory minus Total Obligations
Cash: $48.30M
AR: $0
Inventory: $0
Total Obligations: -$52.99M
$-4.69M
Per share: $-0.06
Period: 2025-12-31
Build your own liquidation scenario
Adjust asset discounts and liability assumptions to see how assumptions affect the numbers.
Liquidation Ladder
| Metric | Total | Per Share |
|---|---|---|
| Cash Liquidation Value | $-4.69M | $-0.06 |
| Liquid Liquidation Value | $-4.69M | $-0.06 |
| Operating Liquidation Value | $-4.69M | $-0.06 |
Key Components (as of 2025-12-31)
| Cash & Equivalents | $48.30M |
| Accounts Receivable | N/A |
| Inventory | N/A |
| Current Liabilities | $51.80M |
| Long-term Debt | N/A |
| Op. Lease Liability | $1.19M |
| Finance Lease | N/A |
| Shares Outstanding | 81.4M |
Explore all 148 XBRL tags and build your own scenario → Open Calculator
Historical
| Period | Cash | AR | Inventory | AP | Curr Liab | LT Debt | Op Lease | Fin Lease |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $48.30M | N/A | N/A | $9.25M | $51.80M | N/A | $1.19M | N/A |
| 2025-09-30 | $35.26M | N/A | N/A | $3.47M | $41.66M | N/A | $1.48M | N/A |
| 2025-06-30 | $52.47M | N/A | N/A | $934,000 | $33.16M | N/A | $1.75M | N/A |
| 2025-03-31 | $50.64M | N/A | N/A | $151,000 | $26.06M | N/A | $1.15M | N/A |
| 2024-12-31 | $139.48M | N/A | N/A | $4.46M | $41.76M | N/A | $1.43M | N/A |
| 2024-09-30 | $35.89M | N/A | N/A | $2.69M | $30.70M | N/A | $1.70M | N/A |
| 2024-06-30 | $16.89M | N/A | N/A | $4.35M | $26.54M | N/A | $1.96M | N/A |
| 2024-03-31 | $33.72M | N/A | N/A | $7.66M | $26.22M | N/A | $2.21M | N/A |
▼ Community Notes